Glucagon-like peptide-1 news

All news on Glucagon-like peptide-1 (also known as GLP-1): plants, production capacities, investments and involved companies.

21 May 2026

Lilly’s retatrutide achieves up to 30% weight loss in Phase 3 TRIUMPH-1

Phase 3 TRIUMPH-1: three doses met endpoints at 80 weeks with dose-related, substantial weight loss. 104-week extension in BMI≥35 showed further loss; cardiometabolic markers improved; GI AEs common.
30 April 2026

Aptar Q1 2026 Results

Q1: sales +11% (core flat); net income -8% to $73M; EPS $1.12 (adjusted $1.19, -8% cc); adjusted EBITDA margin 2% vs 20.7%; returned $131M; Gael Touya named CEO effective Sept 1, 2026
2 March 2026

Novo Nordisk Invests €432M in Athlone Facility Expansion

The investment boosts GLP-1 production, creates 500 construction jobs, and enhances Ireland's role in global supply outside the US. Completion expected by 2028.
25 February 2026

Novo Nordisk and Vivtex Collaborate on Oral Medicines for Obesity and Diabetes

The partnership aims to develop oral biologics for obesity and diabetes, leveraging Vivtex's technology for better bioavailability and Novo Nordisk's expertise in global development and commercialization.
24 February 2026

Novo Nordisk's UBT251 Achieves 19.7% Weight Loss in Phase 2 China Trial

UBT251, a triple agonist, showed significant weight loss and improved health markers in a Chinese phase 2 trial, with a safe and well-tolerated profile.
30 January 2026

Lilly to Build $3.5B Manufacturing Facility in Pennsylvania

The new facility will create 2,800 jobs, produce weight-loss medicines, and boost the local economy with advanced technologies and partnerships in education and workforce development.

Who will be producing Glucagon-like peptide-1 in the future?

Find out with chemXplore Alpha

Learn more